ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Mispro Expands Boston Footprint with Contract Vivarium Facility at Southline

Mispro has announced the opening of its eighth Boston-area contract vivarium, located at Southline Boston in Dorchester—reinforcing its role as the region’s most deeply embedded and consistently scaled vivarium space and services provider.

Located within Southline’s 700,000+ square foot life sciences campus, the new facility expands Mispro’s support for early- and growth-stage biotechs across Greater Boston. As the first company to introduce the contract vivarium (CV) model to the metro area, Mispro remains a critical partner to venture-backed startups and established programs seeking speed, control, and reproducible data in preclinical development.

“With each new facility, we’re investing in more than square footage—we’re expanding access to a smarter, de-risked model for in vivo research,” said Yohan Tessier, President & COO of Mispro. “The contract vivarium option reduces infrastructure burdens while keeping scientific control where it belongs, which is with the biotech teams who are driving discovery forward.”

Southline is also home to Portal Innovations, a leading early-stage venture firm and life sciences incubator. The proximity of Mispro’s vivarium services offers immediate operational advantages to Portal’s member companies and other tenants.

”Having Mispro onsite brings in vivo capacity directly into the heart of our ecosystem, giving early-stage teams immediate access to high-quality preclinical capabilities,” said Portal’s Executive Director in Boston, Tatiana Yglesias. “This streamlined access supports lean operations, accelerates timelines, protects IP, and meaningfully de-risks development—key advantages in today’s fast-moving and capital-conscious funding environment.”

To date in 2025, 75% of biotech M&A activity has involved companies conducting studies in Mispro facilities. The company currently supports 45 Boston-area biotechs and continues to grow alongside the region’s expanding R&D ecosystem.

“This expansion reflects our commitment to enabling science that moves—not just forward, but faster,” added Tessier.

Mispro’s Southline contract vivarium facility is set to open in October. Learn more about the location here.

ABOUT MISPRO

Mispro is a leading contract vivarium organization providing biomedical researchers with turnkey, full-service vivarium facilities to conduct preclinical in vivo studies. With locations in metro Boston/Cambridge, New York, Raleigh-Durham (RTP), Philadelphia, South San Francisco, Palo Alto, San Carlos, and Montreal, Mispro enables innovation by offering a flexible, cost-effective alternative to outsourcing early-stage studies or internalizing an in-house vivarium. For more information, visit www.mispro.com.

“With each new facility, we’re investing in more than square footage—we’re expanding access to a smarter, de-risked model for in vivo research,” said Yohan Tessier, President & COO of Mispro.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.